The NCT02475213 trial assessed enoblitizumab and pembrolizumab or retifanlimab in patients with advanced solid tumors, including patients with various tumors expressing B7-H3 such as NSCLC, melanoma, squamous cell cancer of the head and neck, and urothelial cancers [211]. Here, CD276 is linked to melanoma.